PriveBio — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

PriveBio is a private, preclinical-stage biotech founded in 2018 and based in Cambridge, Massachusetts. The company leverages a proprietary platform that mines extensive human proteo-genomic data to discover novel therapeutic targets involved in metabolic dysfunction and fibro-inflammation. Its pipeline is aimed at addressing significant unmet needs in the interconnected cardiorenal metabolic disease space, including obesity, heart failure, MASH, and CKD. As a pre-revenue company, it is positioned to advance its lead programs toward clinical development, capitalizing on the growing understanding of metabolic disease mechanisms.

Cardiorenal Metabolic DiseasesObesityHeart FailureMASH/NASHChronic Kidney Disease

Technology Platform

A proprietary precision medicine platform that mines large-scale human proteomic and genomic datasets to identify and validate novel targets driving metabolic dysfunction and fibro-inflammation in cardiorenal diseases.

Opportunities

The market for cardiorenal metabolic diseases is massive and growing, driven by the global obesity epidemic.

Recent successes of GLP-1 drugs have validated the market but also highlighted an unmet need in treating the inflammatory and fibrotic organ damage that causes morbidity and mortality.

PriveBio's human-data-driven approach could identify novel, high-potential targets to address this gap.

Risk Factors

High scientific risk associated with novel, first-in-class targets where preclinical data may not translate to human efficacy.

Significant financial risk as a private, pre-revenue company dependent on external funding.

Intense competition from large pharmaceutical companies and well-funded biotechs in the metabolic disease space.

Competitive Landscape

PriveBio competes in a crowded and rapidly evolving field. Large players like Novo Nordisk, Eli Lilly, and Pfizer are heavily invested in obesity and metabolic diseases, while numerous biotechs are pursuing novel mechanisms for MASH, heart failure, and CKD. Differentiation will require demonstrating superior efficacy or a unique mechanism that addresses fibro-inflammation directly.

More companies in United States →